Sara M. Soliman

Dr. Sara M. Soliman

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in Drug Delivery
Verified
Journal Article
Open access
SSSara M. Soliman
Sara M. Soliman
SMShaimaa Mosallam
Shaimaa Mosallam
MMMohamed A. Mamdouh
Mohamed A. Mamdouh
Mohammed Abdalla HusseinMohammed Abdalla Hussein
Mohammed Abdalla Hussein
SEShady M. Abd El-Halim
Shady M. Abd El-Halim
Cranberry extract (CBE) is a major source of the antioxidant polyphenolics but suffers from limited bioavailability. The goal of this research was to encapsulate the nutraceutical (CBE), into bile salt augmented liposomes (BSALs) as a promising oral delivery system to potentiate its hepatoprotective impact against dimethylnitrosamine (DMN) induced liver injury in rats. The inclusion of bile salt in the liposomal structure can enhance their stability within the gastrointestinal tract and promote CBE permeability. CBE loaded BSALs formulations were fabricated utilizing a (23) factorial design to explore the impact of phospholipid type (X1), phospholipid amount (X2), and sodium glycocholate (SGC) amount (X3) on BSALs properties, namely; entrapment efficiency percent, (EE%); vesicle size, (VS); polydispersity index; (PDI); zeta potential, (ZP); and release efficiency percent, (RE%). The optimum formulation (F1) exhibited spherical vesicles with EE% of 71.27 ± 0.32%, VS; 148.60 ± 6.46 nm, PDI; 0.38 ± 0.02, ZP; −18.27 ± 0.67 mV and RE%; 61.96 ± 1.07%. Compared to CBE solution, F1 had attenuated DMN-induced hepatic injury, as evidenced by the significant decrease in serum level of ALT, AST, ALP, MDA, and elevation of GSH level, as well as SOD and GPX activities. Furthermore, F1 exhibited an anti-inflammatory character by suppressing TNF-α, MCP-1, and IL-6, as well as downregulation of VEGF-C, STAT-3, and IFN-γ mRNA levels. This study verified that when CBE was integrated into BSALs, F1, its hepatoprotective effect was significantly potentiated to protect the liver against DMN-induced damage. Therefore, F1 could be deliberated as an antioxidant, antiproliferative, and antifibrotic therapy to slow down the progression of hepatic damage.

17 January 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SSSara M. Soliman
Sara M. Soliman
NSNermin Sheta
Nermin Sheta
BIBassant Ibrahim
Bassant Ibrahim
MEMhammad El-Shawwa
Mhammad El-Shawwa
SMShady Mohammed
Shady Mohammed
Brain damage caused by cerebral ischaemia/reperfusion (I/R) can lead to handicapping. So, the present study aims to evaluate the prophylactic and therapeutic effects of geraniol in the form of intranasal polymeric mixed micelle (PMM) on the central nervous system in cerebral ischaemia/reperfusion (I/R) injury. A 32 factorial design was used to prepare and optimize geraniol PMM to investigate polymer and stabilizer different concentrations on particle size (PS) and percent entrapment efficiency (%EE). F3 possessing the highest desirability value (0.96), with a PS value of 32.46 ± 0.64 nm, EE of 97.85 ± 1.90%, and release efficiency of 59.66 ± 0.64%, was selected for further pharmacological and histopathological studies. In the prophylactic study, animals were classified into a sham-operated group, a positive control group for which I/R was done without treatment, and treated groups that received vehicle (plain micelles), geraniol oil, and geraniol micelles intranasally before and after I/R. In the therapeutic study, treated rats received geraniol oil and micelles after I/R. Evaluation of the effect of geraniol on behavior was done by activity cage and rotarod and the analgesic effect tested by hot plate. Anti-inflammatory activity was assessed by measuring interleukin β6, cyclooxygenase-2, hydrogen peroxide, and inducible nitric oxide synthase. Histopathogical examination of cerebral cortices was also done to confirm the results of a biochemical assay. Geraniol nanostructured polymeric mixed micelles showed an enhanced neuro-protective effect compared to geraniol oil, confirming that PMM via intranasal route could be an efficient approach for delivering geraniol directly to the brain through crossing the blood–brain barrier.

20 February 2020 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
SMShady Mohammed
Shady Mohammed
MMMohamed A. Mamdouh
Mohamed A. Mamdouh
Alaadin E. El-HaddadAlaadin E. El-Haddad
Alaadin E. El-Haddad
SSSara M. Soliman
Sara M. Soliman
Curcumin is a dietary compound with accrued evidence of antiviral activity. Poor solubility and permeation renders curcumin a good applicant for incorporation into proniosomes. The intent of this study was to formulate curcumin proniosomal gel for topical application and the evaluation of its in-vitro, ex-vivo activities against Herpes Simplex virus type 1 (HSV-1), as well as molecular docking studies on HSV-1 thymidine kinase proteins. Coacervation phase separation tactic, using 23 full factorial design, was used in the preparation of different proniosomes. Cytotoxicity of the selected formulae (F4 and F8) was evaluated on the Vero cell line. Optimal formulae (F4 and F8) showed entrapment efficiency of 97.15 ± 2.47% and 95.85 ± 2.9%, vesicle size of 173.7 ± 2.26 nm and 206.15 ± 4.17 nm and percentages curcumin released after 3 h of 51.9 ± 1.4% and 50.5 ± 1.1%, respectively. Ex-vivo permeation studies demonstrated that the optimal formulae markedly improved the dermal curcumin delivery. Curcumin proniosomal gel formulae exhibited 85.4% reduction of HSV-1 replication. The ability of curcumin to interact with the key amino acids in the enzyme binding sites of 1KI7, 1KI4, and 1E2P, as indicated by its docking pattern, rationalized its observed activity. Therefore, curcumin proniosomes could be considered as a successful topical delivery system for the treatment of HSV-1.

1 June 2022 in Bulletin of Pharmaceutical Sciences. Assiut
Verified
Journal Article
Closed access
PDF file
KAKhaled E. Abuelella
Khaled E. Abuelella
HAHend Abd-Allah
Hend Abd-Allah
SSSara M. Soliman
Sara M. Soliman
MAMona M. A. Abdel-Mottaleb
Mona M. A. Abdel-Mottaleb
Recently, the use of biodegradable polymers for specialized applications such as controlled release of drug formulations gained considerable attention. Biodegradable nanoparticles have been widely utilized in drug delivery systems. In this work polyelectrolyte complexation was used to prepare chitosan nanoparticles. The preparation process and major parameters were discussed and optimized. The nanoparticles were prepared by the polyelectrolyte complexation of chitosan (CS) with hyaluronate (HA). Studies were performed to identify effect of chitosan and hyaluronate molecular weight, chitosan: hyaluronate mass ratio and the effects of the aqueous chitosan solution pH on the particle size of nanoparticles. Nanoparticles were characterized by particle size analysis, polydispersity index, zeta potential and transmission electron microscope (TEM). Results showed that nanoparticles could be prepared only within an optimal zone of appropriate chitosan and hyaluronate molecular weights and CS:HA mass ratio. Increasing the hyaluronate molecular weight from low to high led to a significant enlargement in the particle size of the prepared nanoparticles with different chitosan molecular weights. Besides, we found that increasing the hyaluronate content at mass ratio 1:2 of CS:HA led to precipitation of nanoparticles . The particle sizes of the chitosan/HA nanoparticles significantly decreased with the increase of chitosan solution pH. The spherical shaped chitosan/HA nanoparticles were confirmed by TEM. The study showed that systematic design and modulation of the particle size of chitosan/HA polyelectrolyte complexes can be readily achieved with right control of critical processing parameters.

29 December 2025 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Open access
PDF file
Khaled E. AbuelellaKhaled E. Abuelella
Khaled E. Abuelella
SMShimaa Mosalm
Shimaa Mosalm
AEAmira A. El-Gazar
Amira A. El-Gazar
AEAhmed Elshafeey
Ahmed Elshafeey
SSSara M. Soliman
Sara M. Soliman
Purpose: Polycaprolactone nanoparticles (PCLNPs) are biodegradable carriers widely investigated for drug delivery applications. Their hydrophobic nature and high encapsulation efficiency make them ideal for sustained drug release. This study aimed to encapsulate licofelone (LF), a dual COX/5-LOX inhibitor, within PCLNPs to enhance its therapeutic efficacy for osteoarthritis treatment through transdermal administration. Methods: LF loaded PCLNPs were formulated using the nanoprecipitation method. A 2 3 full factorial design was employed by varying PCL (100 or 150 mg), PVA (150 or 300 mg), and SDC (10 or 20 mg) at two levels each. The optimum formula was F8, consisting of 150 mg PCL, 300 mg PVA, and 20 mg SDC. Results: F8 formulation exhibited a spherical shape with a particle size (PS) of 269.3 ± 1.90 nm, an encapsulation efficiency (EE%) of 89 ± 0.56%, a polydispersity index (PDI) of 0.21 ± 0.02, and a zeta potential (ZP) of -27.85 ± 0.07 mV. The F8 gel exhibited a sustained-release profile, with drug permeation across excised rat skin 2.47-fold higher than that of the LF gel ( n = 3, p < 0.05). In vivo evaluation revealed significant chondroprotective and regenerative effects in a monoiodoacetate (MIA)-induced osteoarthritis rat model. F8 gel suppressed the release of inflammatory and pain mediators (5-LOX, COX, LTB 4 , and PGE2) and serum cartilage degradation products (CTX-II and COMP) after 10 days of treatment. Histological evaluation further confirmed its ability to prevent cartilage surface depletion and matrix loss. Conclusion: The optimized F8 gel achieved sustained LF release for approximately 20 h, enhanced ex vivo permeation by 2.47-fold relative to LF gel, and significantly reduced inflammatory mediators and cartilage degradation markers in vivo, highlighting its potential as a promising transdermal therapy for osteoarthritis management. Graphical

22 January 2022 in Bulletin of Pharmaceutical Sciences. Assiut
Verified
Journal Article
Closed access
SSSara M. Soliman
Sara M. Soliman
KRKareem O. Rashwan
Kareem O. Rashwan
GAGhada A. Abdelbary
Ghada A. Abdelbary
MEMohamed A. El-Nabarawi
Mohamed A. El-Nabarawi
NGNabaweya A. Abd El Gawad
Nabaweya A. Abd El Gawad
Baclofen is a GABA-B receptors agonist and possesses anti-inflammatory properties. It has many gastrointestinal side effects and narrow therapeutic index. Thus, the objective of this study was to produce emulgel for the topical delivery of baclofen so as to evade its side effects. Emulgel containing 1% baclofen were fabricated, evaluated and optimized applying full factorial design (23). Liquid paraffin concentration, cremophor RH 40 concentration, and penetration enhancers type was selected as independent variables in the current study to determine the influence of them on the percentage release of baclofen after 30 minutes. The anti-inflammatory activity of the optimal baclofen emulgel was assessed employing the carragenan-induced rat paw edema method. The formulation E5 was established to fulfill the maximum requisite of an optimum formulation with desirability value of 0.982. The mean percentage inhibition value of E5 after 1 hour of application was significantly higher than Baclofen® tablet, baclofen hydrogel and Voltaren® emulgel. The % relative bioavailability of E5 was 108.9%, 99.8% and 138.6% relative to Baclofen® tablet, Voltaren® emulgel and baclofen hydrogel respectively. Therefore, baclofen emulgel can be utilized as an effective anti-inflammatory for topical drug delivery.